pharmacyclics and j&j gain breakthrough status on there blood cancer drug. "companies that receive the status will have closer communication with top FDA staff to move drugs for serious diseases to market more quickly"
I hope that the company is going to apply for this after the next study. it could cut years off the timeline
Omecamtiv mecarbil is a small molecule activator of cardiac myosin. Omecamtiv mecarbil is being investigated to improve cardiac contractility in subjects with heart failure. We are developing this product in collaboration with Cytokinetics, Inc.
Our R&D organization is focused on a “biology-first” approach to drug target selection that requires modality independence. We recognize our deep expertise in biologic development and manufacturing and the higher success rates for developing biologic medicines. However, we also understand that proficiency in small molecules is required to access the majority of drug targets, and we are committed to maintaining and productively utilizing that expertise.
"Peregrine Pharma currently carries a Zacks Rank #3 (Hold). We expect investor focus to remain on updates on the future development path for bavituximab. Biopharma companies that currently look more attractive include Cytokinetics, Inc. (CYTK) and Targacept, Inc. (TRGT). Both are Zacks Rank #1 stocks (Strong Buy)."